The investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease (EVD) compared to the investigational treatment ZMapp. The new report also shows that early diagnosis and treatment are associated with an increased likelihood of survival from EVD.